Sioux Falls, SD

Avera

Transitional Cell Carcinoma

Carcinoma

Presbyopia

Endometrial Cancer

Pilocarpine

Karyopharm Therapeutics

Ocuphire Pharma

Seagen

condition

allSponsorName

Belgium and Luxembourg Gynaecological Oncology Group (BGOG)

Central and Eastern European Gynecologic Oncology Group (CEEGOG)

European Society of Gynaecological Oncology (ESGO)

GOG Foundation

Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO)

Spanish Ovarian Cancer Research Group (GEICO)

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1.1\]) after completing at least 12 weeks of platinum-based therapy. A total of 220 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo.

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Avera | Sioux Falls, SD

Site insights

Work at this site?

Active trials

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042)

Trial sponsors